The Week

Nutex Health (NUTX) fell 1.64% this week to close at $216.50, underperforming the S&P 500, which slipped 0.27%, by about 1.37 percentage points. The stock opened the week with a push toward $222.13 on Monday before retreating, then hit a weekly low of $206.34 on Tuesday. The following three sessions saw a stabilising climb, with Friday ending at $216.50 on heavier volume. Weekly amplitude was 7.24%, with activity picking up notably into the close. There was no major catalyst during the week, and price kept consolidating near record territory.

Analyst Ratings

Five brokers cover the stock: four rate it buy and one rates it overweight, with no hold, underweight or sell ratings. The consensus rating is strong buy, and the consensus target is $288.20, roughly 33.1% above the latest close. Target prices range from $200 to $325, a wide spread that suggests notable disagreement among analysts. Within its healthcare facilities peer group of 20 names, NUTX ranks 16th by analyst rating.

The Week Ahead

Monday brings the final reading of the S&P Global services PMI (prior 58.7) and the ISM non-manufacturing PMI (prior 55.4, forecast 55). Tuesday includes international trade balance data (prior -88.6, forecast -102) and the goods trade balance (prior -132.6). Wednesday sees the EIA weekly crude oil inventory and Cushing inventory reports. The company itself has no scheduled events next week, so the key question is whether price can hold near the top of its recent range.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.